22 results
8-K
EX-2.1
CHRS
Coherus Biosciences Inc
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
” or “toxic,” or as a “pollutant” or “contaminant,” under any applicable Environmental Law.
“Health Care Payor” means any governmental, commercial or private
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
27 Oct 23
Regulation FD Disclosure
4:19pm
. Exfoliative dermatitis, including Stevens-Johnson Syndrome (SJS), drug rash with eosinophilia and systemic symptoms (DRESS), and toxic epidermal necrolysis
425
SURF
Surface Oncology, Inc.
16 Jun 23
Business combination disclosure
8:08am
or as hazardous, toxic, radioactive or dangerous or any other term of similar import under any Environmental Law, including but not limited to petroleum
425
SURF
Surface Oncology, Inc.
16 Jun 23
Business combination disclosure
7:09am
, pollutant or contaminant or as hazardous, toxic, radioactive or dangerous or any other term of similar import under any Environmental Law, including
8-K
EX-2.1
55n xvjmvva1
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
8-K
EX-10.1
qbe0rmuf506fa6
11 Jan 19
Entry into a Material Definitive Agreement
4:08pm
10-K
r29 be03reot6msu
23 Mar 15
Annual report
12:00am
424B4
1lf2ty6bb214pchi oz
6 Nov 14
Prospectus supplement with pricing info
12:00am
S-1/A
y8vdqme5r0 hn6ovpc
6 Oct 14
IPO registration (amended)
12:00am
DRS/A
ijuydu51o
15 Sep 14
Draft registration statement (amended)
12:00am